BS_196BBNEJ
EPN · Posterior Fossa EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Posterior Fossa EPN
- cancer_type
- EPN
- subtype
- Posterior Fossa EPN
- overall_survival_months
- 51.72
- os_event
- false
- age_years
- 1.03
- sex
- M
- race
- White
- e1_e2
- E2
- umap1_2d
- -5.255900463
- umap2_2d
- -0.245608314
- umap1_3d
- 0.145623129
- umap2_3d
- 2.848187214
- umap3_3d
- 0.092511973
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- CHOLESTEROL_HOMEOSTASIS+0.550
- ANGIOGENESIS+0.420
- NOTCH_SIGNALING+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- WNT_BETA_CATENIN_SIGNALING+0.400
- HYPOXIA+0.390
- APICAL_JUNCTION+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- HEDGEHOG_SIGNALING+0.330
- UV_RESPONSE_UP+0.330
Top 10 suppressed
- PROTEIN_SECRETION-0.300
- INTERFERON_ALPHA_RESPONSE-0.260
- SPERMATOGENESIS-0.220
- MYC_TARGETS_V1-0.200
- PANCREAS_BETA_CELLS-0.140
- E2F_TARGETS-0.120
- G2M_CHECKPOINT-0.080
- ALLOGRAFT_REJECTION-0.070
- OXIDATIVE_PHOSPHORYLATION-0.060
- INTERFERON_GAMMA_RESPONSE-0.040
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_196BBNEJ | Posterior Fossa Ependymoma | — | 0.913 |
| 2 | MNG136 | — | — | 0.850 |
| 3 | 82992 | EPN | Supratentorial EPN | 0.832 |
| 4 | TCGA-60-2707-01A-01R-0851-07 | — | cohortSQ1 | 0.819 |
| 5 | b556b718-38cf-498d-94c7-4e240fe57d48 | — | — | 0.816 |
| 6 | MNG701 | — | — | 0.814 |
| 7 | BS_QP6MSKRE | Spinal Cord Ependymoma | — | 0.812 |
| 8 | BS_RXN5T5YT | Diffuse intrinsic pontine glioma | — | 0.810 |
| 9 | s0112232 | — | — | 0.810 |
| 10 | s0122159 | — | — | 0.807 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| CHOLESTEROL_HOMEOSTASIS | 0.550 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.420 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| HYPOXIA | 0.390 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.330 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| MYOGENESIS | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.290 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.280 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.270 | Inavolisib | — uncovered |
| COAGULATION | 0.250 | Binimetinib | — uncovered |